The FDA resumed publishing complete response letters (CRLs) after a pause designed to support “commitment to transparency,” according to BioCentury coverage and related FDA postings. The resumed batches include multiple pharma CRLs, including a camrelizumab plus rivoceranib combination from Hengrui and Elevar that already faced scrutiny. Separate reporting indicates the agency had previously stopped releasing CRLs amid legal and sensitivity concerns, limiting public visibility into why applications were rejected. The shift back to publication suggests the FDA is balancing regulatory candor with litigation risk while keeping companies informed through official correspondence. For biotech and pharma teams, the operational implication is straightforward: CRL-related signals will again surface more visibly in the market, potentially affecting investor expectations, commercial planning timelines, and resubmission strategies. Companies with late-stage or filing-linked programs may now need to track CRL postings more closely to calibrate next regulatory steps, manufacturing remediation work, and clinical readout interpretation in near-real time.